Ivan Kuhajda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ivan Kuhajda has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Marko Bojovic
University of Novi Sad, Faculty of Medicine in Novi Sad, Novi Sad, Serbia; Clinic for Radiation Oncology, Oncology Institute of Vojvodina, Novi Sad, Serbia
3 shared publications - Nensi Lalic
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
3 shared publications Danijela Kuhajda
University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia + Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia
2 shared publications- Ivan Ergelasev
University of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, Serbia + Institute for Pulmonary Diseases of Vojvodina, Thoracic Surgery Clinic, Novi Sad - Sremska Kamenica, Serbia
2 shared publications Sinisa Maksimovic
University of Novi Sad, Faculty of Medicine, Department of Obstetrics and Gynecology, Novi Sad + Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica
2 shared publications- Aleksandra Vulin
University of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, Serbia + Institute for Cardiovascular Diseases of Vojvodina, Clinic for cardiology, Novi Sad - Sremska Kamenica, Serbia
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 73
Can heart rate variability be utilised to predict compensatory sweating after endoscopic thoracic sympathicotomy in patients with primary focal hyperhidrosis?
Introduction/Objective. Hyperhidrosis is a condition of pathological excessive sweating that exceeds the body’s physiological requirements for thermoregulation. Endoscopic thoracic sympathicotomy (ETS) is a commonly used treatment for primary focal hyperhidrosis (PFH); however, it may result in compensatory sweating (CS), which represents its most frequent postoperative complication. This study aimed to investigate whether heart rate variability (HRV) parameters could predict CS. Methods. A prospective single-center study was conducted in 100 patients with primary focal hyperhidrosis (PFH) who underwent ETS. Preoperatively, all patients underwent 24-hour Holter ECG monitoring to assess standard HRV parameters. ETS was performed by transection of the sympathetic chain at the level of the third (R3) and fourth rib (R4), including the accessory Kuntz fibers. One month after surgery, the presence and severity of CS were assessed. Results. CS was absent in 61% of patients (p=0.028). Mild CS was the most common form (p < 0.01). No statistically significant differences were observed in the analyzed preoperative HRV parameters between patients with and without CS (p > 0.05), including the low-frequency (LF)/high-frequency (HF) ratios, which represent balanced autonomic activity (LF/HF < 2) and sympathetic predominance (LF/HF ≥ 2). ROC curve analysis showed that age had significant predictive accuracy for CS (AUC 0.7333; 95% CI 0.634-0.833; p < 0.01), with an optimal cutoff of 23.5 years (sensitivity 0.82, specificity 0.47). Conclusion. HRV parameters cannot reliably predict CS following bilateral ETC in patients with PFH. The study confirmed that the optimal age for surgery is below 23.5 years.
- 1 January 2026
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- No. 00,p. 73
Open AccessCan heart rate variability be utilised to predict compensatory sweating after endoscopic thoracic sympathicotomy in patients with primary focal hyperhidrosis?
Introduction/Objective. Hyperhidrosis is a condition of pathological excessive sweating that exceeds the body’s physiological requirements for thermoregulation. Endoscopic thoracic sympathicotomy (ETS) is a commonly used treatment for primary focal hyperhidrosis (PFH); however, it may result in compensatory sweating (CS), which represents its most frequent postoperative complication. This study aimed to investigate whether heart rate variability (HRV) parameters could predict CS. Methods. A prospective single-center study was conducted in 100 patients with primary focal hyperhidrosis (PFH) who underwent ETS. Preoperatively, all patients underwent 24-hour Holter ECG monitoring to assess standard HRV parameters. ETS was performed by transection of the sympathetic chain at the level of the third (R3) and fourth rib (R4), including the accessory Kuntz fibers. One month after surgery, the presence and severity of CS were assessed. Results. CS was absent in 61% of patients (p=0.028). Mild CS was the most common form (p < 0.01). No statistically significant differences were observed in the analyzed preoperative HRV parameters between patients with and without CS (p > 0.05), including the low-frequency (LF)/high-frequency (HF) ratios, which represent balanced autonomic activity (LF/HF < 2) and sympathetic predominance (LF/HF ≥ 2). ROC curve analysis showed that age had significant predictive accuracy for CS (AUC 0.7333; 95% CI 0.634-0.833; p < 0.01), with an optimal cutoff of 23.5 years (sensitivity 0.82, specificity 0.47). Conclusion. HRV parameters cannot reliably predict CS following bilateral ETC in patients with PFH. The study confirmed that the optimal age for surgery is below 23.5 years.
- Open Access
- 1 January 2024
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 152 (7-8) , 363-367
Evaluation of the quality of life 10 years after bilateral thoracoscopic sympathicotomy in subjects with primary focal hyperhidrosis
Introduction/Objective. Primary focal hyperhidrosis (PFH) is an idiopathic condition where excessive sweating affects one or more body regions, including axillae, palms, soles, and/or face. Most studies on quality-of-life (QoL) focus on the period up to one year after bilateral thoracoscopic sympathectomy (BTS). This study aims to determine the 10-year trend in QoL among patients from the Republic of Serbia with palmar-plantar-axillary PFH, treated with BTS at the R3?R4 level. A secondary goal is to ascertain the existence of compensatory sweating. Methods. All patients underwent a standardized BTS in a single act, through the cutting of ganglia with ultrasonic scissors at the R3?R4 level. For data collection, patients completed the ?Hyperhidrosis Quality of Life Questionnaire,? and the Hyperhidrosis Disease Severity Scale, preoperatively, postoperatively within 30 days, and 10 years after BTS. Results. The total sample consisted of 103 subjects who completed all three questionnaires. Considering the improvement in QoL from the group excellent, good, and average, the postoperative improvement was immediately postoperative in 88.4% of patients, while in the ten-year period, it was 87.4%. No statistically significant differences were found between the assessment of life satisfaction after 30 days and 10 years after BTS. Out of the total number of operated patients, two patients (1.94%) characterized their compensatory sweating as very pronounced. Conclusion. After 10 years from BTS, the QoL remains at an exceptionally high level, with an annual trend of decline of about 0.1%.
- 1 January 2024
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 152 (7-8) , 363-367
Open AccessEvaluation of the quality of life 10 years after bilateral thoracoscopic sympathicotomy in subjects with primary focal hyperhidrosis
Introduction/Objective. Primary focal hyperhidrosis (PFH) is an idiopathic condition where excessive sweating affects one or more body regions, including axillae, palms, soles, and/or face. Most studies on quality-of-life (QoL) focus on the period up to one year after bilateral thoracoscopic sympathectomy (BTS). This study aims to determine the 10-year trend in QoL among patients from the Republic of Serbia with palmar-plantar-axillary PFH, treated with BTS at the R3?R4 level. A secondary goal is to ascertain the existence of compensatory sweating. Methods. All patients underwent a standardized BTS in a single act, through the cutting of ganglia with ultrasonic scissors at the R3?R4 level. For data collection, patients completed the ?Hyperhidrosis Quality of Life Questionnaire,? and the Hyperhidrosis Disease Severity Scale, preoperatively, postoperatively within 30 days, and 10 years after BTS. Results. The total sample consisted of 103 subjects who completed all three questionnaires. Considering the improvement in QoL from the group excellent, good, and average, the postoperative improvement was immediately postoperative in 88.4% of patients, while in the ten-year period, it was 87.4%. No statistically significant differences were found between the assessment of life satisfaction after 30 days and 10 years after BTS. Out of the total number of operated patients, two patients (1.94%) characterized their compensatory sweating as very pronounced. Conclusion. After 10 years from BTS, the QoL remains at an exceptionally high level, with an annual trend of decline of about 0.1%.
- 31 August 2023
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Respiratio
- Vol. 13 (1-2) , 95-101
Skrining karcinoma pluća u AP Vojvodini - Lung cancer screening in Vojvodina province
Introduction Better survival of lung cancer (LC) patients is possible if the diagnosis is made early in the disease course. Low-dose CT in a high-risk population for developing LC enables cancer detection in the earlier stages of the disease and improves survival. Method LC screening with low-dose CT was performed at the Institute for Pulmonary Diseases of Vojvodina (IPBV) from September 2020 to December 2022. People aged 50-74 years, ex-smokers (started smoking 10 years ago) and active smokers with •30 pack-years, or •20 pack-years with additional risk factors, were included. We retrospectively analyzed screen population characteristics, screening results (according to Lung-RADS score) and definite findings of suspicious nodules by histological type and LC stage by gender. Results During the observed period, a total of 3432 LDCT scans were performed, of which 62.3% (2138) were baseline LDCT. Suspicious and highly suspicious nodule findings (Lung-RADS 4) were observed in 196 (9.2%) subjects. The emphysema was registered in 709 (33.2%) subjects. The LC detection rate was 1.8% (40/2138). 88.5% (23/26) of confirmed LC were detected after the initial LDCT, while the remaining 11.5% (3/26) were established after the follow-up period. 75% (30/40) of LC were in stages I to IIIA. Non-small cell lung cancer (adenocarcinoma 60.0% (24/40), squamous cancers 22.5% (9/40) and other non-small cell cancers (NOS) 5.0% (2/40)) accounted for 85.7% (35/40), while small cells lung cancer was present in 12.5% (5/40). Conclusion Most LC cases were detected in the early stage of the disease. Therefore, screening for LC should cover the high-risk population in the territory of the entire Republic.
- 31 August 2023
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Respiratio
- Vol. 13 (1-2) , 95-101
Skrining karcinoma pluća u AP Vojvodini - Lung cancer screening in Vojvodina province
Introduction Better survival of lung cancer (LC) patients is possible if the diagnosis is made early in the disease course. Low-dose CT in a high-risk population for developing LC enables cancer detection in the earlier stages of the disease and improves survival. Method LC screening with low-dose CT was performed at the Institute for Pulmonary Diseases of Vojvodina (IPBV) from September 2020 to December 2022. People aged 50-74 years, ex-smokers (started smoking 10 years ago) and active smokers with •30 pack-years, or •20 pack-years with additional risk factors, were included. We retrospectively analyzed screen population characteristics, screening results (according to Lung-RADS score) and definite findings of suspicious nodules by histological type and LC stage by gender. Results During the observed period, a total of 3432 LDCT scans were performed, of which 62.3% (2138) were baseline LDCT. Suspicious and highly suspicious nodule findings (Lung-RADS 4) were observed in 196 (9.2%) subjects. The emphysema was registered in 709 (33.2%) subjects. The LC detection rate was 1.8% (40/2138). 88.5% (23/26) of confirmed LC were detected after the initial LDCT, while the remaining 11.5% (3/26) were established after the follow-up period. 75% (30/40) of LC were in stages I to IIIA. Non-small cell lung cancer (adenocarcinoma 60.0% (24/40), squamous cancers 22.5% (9/40) and other non-small cell cancers (NOS) 5.0% (2/40)) accounted for 85.7% (35/40), while small cells lung cancer was present in 12.5% (5/40). Conclusion Most LC cases were detected in the early stage of the disease. Therefore, screening for LC should cover the high-risk population in the territory of the entire Republic.
- 1 January 2022
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 75 (1-2) , 45-49
Malignant pleural effusion in patients with ovarian cancer
Introduction. Ovarian cancer is the most lethal gynecological cancer. The most common manifestation of thoracic metastasis is pleural effusion. Pleural effusion with positive cytology is regarded as stage IVa of the International Federation of Gynecology and Obstetrics classification, and the overall five-year survival in these patients is less than 20%. We analyzed the data of patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina, in order to establish the incidence of malignant pleural effusions, laterality of pleural effusions, and clinical manifestations. Material and Methods. The study included 731 patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina from January 2012 to May 2020. The obtained data were compared with data found in the literature in the same period. Results. The incidence of malignant pleural effusion in our study was 5.75%; right-sided pleural effusion was found in 57.15% of patients, 33.33% of patients had effusion on the left side, and 9.52% had bilateral effusions. Thus, unilateral effusion was found in 90.48% of cases, and bilateral in only 9.52%. The most common symptom was dyspnea, reported in 33 patients (78.6%). Conclusion. The incidence of malignant pleural effusion in our study was most similar to data found by Zamboni et al. published in 2015; the right side was the dominant side of pleural effusions. The most common symptoms were dyspnea, shortnes of breath and chest pain.
- 1 January 2022
- Published by National Library of Serbia in Medicinski Pregled
- Vol. 75 (1-2) , 45-49
Malignant pleural effusion in patients with ovarian cancer
Introduction. Ovarian cancer is the most lethal gynecological cancer. The most common manifestation of thoracic metastasis is pleural effusion. Pleural effusion with positive cytology is regarded as stage IVa of the International Federation of Gynecology and Obstetrics classification, and the overall five-year survival in these patients is less than 20%. We analyzed the data of patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina, in order to establish the incidence of malignant pleural effusions, laterality of pleural effusions, and clinical manifestations. Material and Methods. The study included 731 patients with ovarian cancer who were treated at the Oncology Institue of Vojvodina from January 2012 to May 2020. The obtained data were compared with data found in the literature in the same period. Results. The incidence of malignant pleural effusion in our study was 5.75%; right-sided pleural effusion was found in 57.15% of patients, 33.33% of patients had effusion on the left side, and 9.52% had bilateral effusions. Thus, unilateral effusion was found in 90.48% of cases, and bilateral in only 9.52%. The most common symptom was dyspnea, reported in 33 patients (78.6%). Conclusion. The incidence of malignant pleural effusion in our study was most similar to data found by Zamboni et al. published in 2015; the right side was the dominant side of pleural effusions. The most common symptoms were dyspnea, shortnes of breath and chest pain.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 150 (1-2) , 35-40
Risk factors as outcome predictors of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease
Introduction/Objective. Chronic obstructive pulmonary disease (COPD) is a primary lung disease. Today, pulmonary rehabilitation (PR) is the basis for non-pharmacological treatment of these patients, with numerous confirmed effects on the most significant symptoms of the disease and the quality of life (QoL). The aim of this study was to determine the relationship between certain risk factors and the outcome of PR, as well as to determine the percentage of respondents who had a positive outcome of PR. Methods. The study included 500 patients with COPD, determined according to the Global Initiative for Chronic Obstructive Lung Disease guidelines, all stages (I?IV), in the stable phase of the disease, who completed the outpatient PR program. Disease stage, comorbidities, forced expiratory volume in the first second, six-minute walk test (6MWT), COPD Assessment Test (CAT), and Medical Research Council dyspnea scale, body mass index, airflow obstruction, dyspnea and exercise capacity (BODE) index, were measured before and after the program. The last four parameters have been observed as risk factors that affect the outcome of PR, but also as parameters by which we monitor the outcome of PR. Results. A successful outcome of PR was achieved by as many as 452 (90.4%) patients. The following were determined as independent predictors of a positive outcome of PR: lower number of comorbidities, absence of heart failure, higher BMI, and CAT ? 10. Conclusions. PR in our group of patients leads to statistically significant improvements in most of the examined subjective and objective parameters, in patients in all stages of the disease.
- 1 January 2022
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 150 (1-2) , 35-40
Open AccessRisk factors as outcome predictors of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease
Introduction/Objective. Chronic obstructive pulmonary disease (COPD) is a primary lung disease. Today, pulmonary rehabilitation (PR) is the basis for non-pharmacological treatment of these patients, with numerous confirmed effects on the most significant symptoms of the disease and the quality of life (QoL). The aim of this study was to determine the relationship between certain risk factors and the outcome of PR, as well as to determine the percentage of respondents who had a positive outcome of PR. Methods. The study included 500 patients with COPD, determined according to the Global Initiative for Chronic Obstructive Lung Disease guidelines, all stages (I?IV), in the stable phase of the disease, who completed the outpatient PR program. Disease stage, comorbidities, forced expiratory volume in the first second, six-minute walk test (6MWT), COPD Assessment Test (CAT), and Medical Research Council dyspnea scale, body mass index, airflow obstruction, dyspnea and exercise capacity (BODE) index, were measured before and after the program. The last four parameters have been observed as risk factors that affect the outcome of PR, but also as parameters by which we monitor the outcome of PR. Results. A successful outcome of PR was achieved by as many as 452 (90.4%) patients. The following were determined as independent predictors of a positive outcome of PR: lower number of comorbidities, absence of heart failure, higher BMI, and CAT ? 10. Conclusions. PR in our group of patients leads to statistically significant improvements in most of the examined subjective and objective parameters, in patients in all stages of the disease.
- Open Access
- 1 January 2021
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 149 (5-6) , 343-347
COVID-19 pneumonia complicated by late presentation of bilateral spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema
Introduction. Over the last few months the coronavirus disease 2019 (COVID-19) pandemic has created overwhelming challenges for physicians across the world. While much has been described in the literature about lung infiltrates and respiratory failure associated with infection of coronavirus 2 (SARS-CoV-2), pneumothorax is reported as a rare (a rate of one percent) but life-threatening complication of COVID-19 pneumonia. Late bilateral spontaneous pneumothorax has been described in only few cases. The aim of the review is to consider pneumothorax as a possible complication of COVID-19 pneumonia, which is also one of the causes of respiratory deterioration and potentially fatal outcome in these patients. Case Outline. This article describes the clinical course of the patient who tested positive for SARS-CoV-2 on reverse-transcriptase polymerase chain reaction (RT-PCR) testing of nasopharyngeal and oropharyngeal swab specimens and who presented with COVID-19 pneumonia complicated by bilateral, spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema. He didn't have underlying lung disease or risk factors for pneumothorax, except administered NIV/CPAP during first hospitalization. The patient was successfully treated with surgical (chest drainage, thoracoscopy and pleural abrasion) and non-surgical methods (by application of drugs and other supportive therapies). Conclusion This review demonstrates that the possibility of a late pneumothorax should be kept in mind in patients with, or recovering from, COVID-19 disease with progressive dyspnea. The timely diagnosis and management of pneumothorax will reduce COVID-19 associated mortality.
- 1 January 2021
- Published by National Library of Serbia in Srpski arhiv za celokupno lekarstvo
- Vol. 149 (5-6) , 343-347
Open AccessCOVID-19 pneumonia complicated by late presentation of bilateral spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema
Introduction. Over the last few months the coronavirus disease 2019 (COVID-19) pandemic has created overwhelming challenges for physicians across the world. While much has been described in the literature about lung infiltrates and respiratory failure associated with infection of coronavirus 2 (SARS-CoV-2), pneumothorax is reported as a rare (a rate of one percent) but life-threatening complication of COVID-19 pneumonia. Late bilateral spontaneous pneumothorax has been described in only few cases. The aim of the review is to consider pneumothorax as a possible complication of COVID-19 pneumonia, which is also one of the causes of respiratory deterioration and potentially fatal outcome in these patients. Case Outline. This article describes the clinical course of the patient who tested positive for SARS-CoV-2 on reverse-transcriptase polymerase chain reaction (RT-PCR) testing of nasopharyngeal and oropharyngeal swab specimens and who presented with COVID-19 pneumonia complicated by bilateral, spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema. He didn't have underlying lung disease or risk factors for pneumothorax, except administered NIV/CPAP during first hospitalization. The patient was successfully treated with surgical (chest drainage, thoracoscopy and pleural abrasion) and non-surgical methods (by application of drugs and other supportive therapies). Conclusion This review demonstrates that the possibility of a late pneumothorax should be kept in mind in patients with, or recovering from, COVID-19 disease with progressive dyspnea. The timely diagnosis and management of pneumothorax will reduce COVID-19 associated mortality.